This also applies for patients co-infected with HIV, where pre-treatment IP-10 levels below 150 pg/mL are predictive of a favorable response, and may thus be useful in encouraging these otherwise difficult-to-treat patients to initiate therapy. The pathogen Leishmania major utilizes a protease, GP63, that cleaves CXCL10, implicating CXCL10 in host defense mechanisms of certain intracellular pathogens like Leishmania.
This also applies to HIV-infected individuals who have co-infection, where pre-treatment IP-10 levels below 150 pg/mL are indicative of a favorable response, and may be useful in motivating these hard-to-treat patients to initiate therapy. The parasite Leishmania major employs an enzyme, GP63, that cleaves CXCL10, suggesting CXCL10's role in the defense mechanisms of certain internal pathogens such as Leishmania.